ClinicalTrials.gg
RecruitingNCT06782412FAPIDOUpdated Nov 6, 2026

Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types

A Phase 2/3 interventional study of [18F]AlF-FAPI-74 PET/CT in Oesophageal Cancer, Gastric Cancer and Pancreatic Ductal Adenocarcinoma, sponsored by KU Leuven. Recruiting at 3 sites in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by KU Leuven · Phase 2/3, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.
Updated Nov 6, 20261 site added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
109
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Esophageal Neoplasms with a site in Belgium — 17 open to participants now, 22 under way, 5 of them phase 3. Esophageal Neoplasms · Belgium.

Planned enrollment
20th of 32
109 · median 198
Started
2025
with 1 other
Phase 2/3
Only one
of the 41
Primary completion
2027-12
later than 10 of 21 live
Registered
40th of 41
by date
Lead sponsor
3 of 41
KU Leuven

Among the 41 studies in Esophageal Neoplasms with a site in Belgium, this one is the 20th largest by planned enrollment of the 32 interventional ones that give a count, is one of 2 that started in 2025, is the only one in phase 2/3, reaches primary completion later than 10 of the 21 other live ones, and was the 40th registered.

Esophageal Neoplasms

1,874 studies on the registry are indexed under Esophageal Neoplasms; 502 are open to participants now.

Browse Esophageal Neoplasms studies →

Open to participants now

17 of the 41 studies in Esophageal Neoplasms with a site in Belgium are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 387 Esophageal Neoplasms studies recruiting now, 245 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Esophageal Neoplasms with a site in Belgium, or all of them as a file.
02

Study summary

The aim of the project is to demonstrate superior detection ratio of [18F]AlF-FAPI-74 PET/CT compared to [18F]FDG PET/CT or conventional imaging in treatment-naïve, newly diagnosed patients with oesophagogastric adenocarcinoma (clinical T1-4N0-3M0) and pancreatic ductal adenocarcinoma (clinical T1-4N0-2M0-1) and describe the clinical utility of [18F]AlF-FAPI-74 PET/CT in oncological patients with a clinically challenging situation.

03

Conditions studied

  • Oesophageal Cancer
  • Gastric Cancer
  • Pancreatic Ductal Adenocarcinoma
  • FAP
  • Oncology
  • Oncologic Disorders

Keywords

  • Oesophagogastric adenocarcinoma
  • Pancreatic ductal adenocarcinoma
  • Clinically challenging situations
  • [18F]-FDG
  • [18F]-FAPI-74
  • [18F]AIF-FAPI-74
  • Positron emission tomography
  • PET
  • Nuclear imaging
  • Oncology
  • Prospective
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria OGA:

  1. Voluntary written of the participant or their legally authorized representative has been obtained prior to any screening procedures.
  2. Age 18 or older.
  3. New histologic or cytologic proven diagnosis of oesophagogastric adenocarcinoma.
  4. Patient underwent a [18F]FDG PET/CT.
  5. TNM classification: cT1-4N0-3M0

Inclusion Criteria PDAC:

  1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures.
  2. Age 18 or older.
  3. New histologic or cytologic proven diagnosis of pancreatic ductal adenocarcinoma.
  4. Patient underwent a [18F]FDG PET/CT or conventional staging with CT or MRI.
  5. TNM classification: cT1-4N0-2M0-1, with the exception of upfront resectable patients.

Inclusion Criteria Clinically challenging cohort:

  1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures.
  2. Age 18 or older.
  3. Histologic or cytologic proven diagnosis of a .
  4. Patient underwent a [18F]FDG PET/CT.
  5. Unexplained symptoms, complaints, biochemical or imaging (scintigraphy, PET, CT, MR) findings.

Exclusion Criteria:

  1. Participant is mentally or legally incapacitated, doesn't understand the study design or is not willing or capable to undergo all study-specific procedures.
  2. Any disorder or condition, which in the Investigator's opinion might jeopardise the participant's safety or compliance with the protocol.
  3. Any prior or concomitant treatment(s) that might jeopardise the participant's safety or that would compromise the integrity of the Trial.
  4. Female who is pregnant (urinary hCG test can be performed in case of doubt), breast-feeding or intends to become pregnant or is of and not using an adequate, highly effective (with a relatively high Pearl Index: natural methods, minipill outside postpartum period, spermicides or condoms in monotherapy or no usage of contraception when sexually active are not accepted).
  5. Participation in an interventional Trial with an medicinal product (IMP) or device when the trial designs are not considered compatible by the study team.
  6. Participation in a clinical scientific study in the last 12 months with a radiation exposure caused by the experimental procedures greater than 1 mSv.
  7. Participant has a known to [18F]AlF-FAPI-74 or the used .
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
109 participants (estimated)

Study arms

  • Experimental
    Oesophagogastric adenocarcinoma (OGA)

    Diagnostic Test: [18F]AlF-FAPI-74 PET/CT

  • Experimental
    Pancreatic ductal adenocarcinoma (PDAC)

    Diagnostic Test: [18F]AlF-FAPI-74 PET/CT

  • Experimental
    Clinically challenging situations

    Diagnostic Test: [18F]AlF-FAPI-74 PET/CT

Interventions

  • Diagnostic test[18F]AlF-FAPI-74 PET/CT

    A \[18F\]AlF-FAPI-74 PET/CT will be performed at the same site of the screening visit (UZ Leuven, UZ Gent or UZ Antwerpen). Subjects are required to be sober four hours before the scan. The patient will get an IV line, through which the \[18F\]AlF-FAPI-74 will be injected in one bolus (3,5 MBq/kg). After 60 minutes, the acquisition on the PET/CT scan will take place. The CT will be a low dose CT with oral contrast. After the scan, participants will be observed at the department in case of adverse events. During this time, the participant can fill in the PRO. The estimated duration of this visit is three hours. If the patient receives neo-adjuvant therapy, a second \[18F\]AlF-FAPI-74 PET/CT will be performed maximum one month before surgery. If the planned surgery gets postponed after the second \[18F\]AlF-FAPI-74 PET/CT has been performed, we will have the possibility to perform one additional (i.e. third) \[18F\]AlF-FAPI-74 PET/CT, before the final surgery.

06

What researchers measure

Primary outcomes

  1. Primary Objective OGA: demonstrate superiority of [18F]AlF-FAPI-74 PET/CT over [18F]FDG PET/CT.

    Detection ratio for lymph node and distant metastases (combined).

    Time frame: From enrollment to the end of the follow-up period (i.e. 12 months after first [18F]AlF-FAPI-74 PET/CT)

  2. Primary Objective PDAC: demonstrate superiority of [18F]AlF-FAPI-74 PET/CT over conventional imaging (CT or MRI) or [18F]FDG PET/CT (if available)

    Detection ratio for lymph node and distant metastases (combined).

    Time frame: From enrollment to the end of the follow-up period (i.e. 12 months after first [18F]AlF-FAPI-74 PET/CT)

  3. Primary Objective Clinically Challenging Situation: demonstrate contribution of [18F]AlF-FAPI-74 PET/CT in this setting.

    Fraction of patients were scan was deemed contributory. This means: 1. \[18F\]AlF-FAPI-74 identifies a lesion as malignant (true positive) with effective upstaging. 2. \[18F\]AlF-FAPI-74 identifies a lesion as non-malignant (true negative) with effective downstaging. 3. \[18F\]AlF-FAPI-74 can differentiate between a malignant or non-malignant lesion when there is doubt. 4. Other implications that are deemed contributory by the treating physician.

    Time frame: From enrollment to the end of the follow-up period (i.e. 12 months after first [18F]AlF-FAPI-74 PET/CT)

Secondary outcomes

  1. OGA & PDAC: Detection ratio for tumor detection

    primary tumor alone; lymph nodes alone (N-staging); distant metastases alone (M-staging) and lymph node + distant metastases combined (with inclusion of patients without N- or M-lesions).

    Time frame: From enrollment to the end of the follow-up period (i.e. 12 months after first [18F]AlF-FAPI-74 PET/CT)

  2. OGA & PDAC: specificity, positive and negative predictive value and accuracy

    Specificity, positive predictive value, negative predictive value, accuracy for lymph node and distant metastases (combined); for detection of primary tumor; for lymph nodes alone (N-staging); for distant metastases alone (M-staging).

    Time frame: From enrollment to the end of the follow-up period (i.e. 12 months after first [18F]AlF-FAPI-74 PET/CT)

  3. OGA & PDAC: positive and negative likelihood ratios; diagnostic odds ratio.

    Positive and negative likelihood ratios; diagnostic odds ratio.

    Time frame: From enrollment to the end of the follow-up period (i.e. 12 months after first [18F]AlF-FAPI-74 PET/CT)

  4. OGA & PDAC: semi-quantitative uptake measurements

    Semi-quantitative uptake measurements (maximal standardized uptake value (SUVmax), average SUV (SUVmean), peak SUV (SUVpeak) of tumoral lesions on \[18F\]AlF-FAPI-74 PET/CT and \[18F\]FDG PET/CT.

    Time frame: From enrollment to the end of the follow-up period (i.e. 12 months after first [18F]AlF-FAPI-74 PET/CT)

  5. OGA & PDAC: tumor-to-background uptake values

    Tumor-to-background uptake values (TBR; SUV lesion divided by SUV background) for \[18F\]AlF-FAPI-74 PET/CT and \[18F\]FDG PET/CT, using following background organs: liver, lung, gluteus muscle, mediastinal bloodpool, bowel, bone marrow (L4 if no abnormal uptake).

    Time frame: From enrollment to the end of the follow-up period (i.e. 12 months after first [18F]AlF-FAPI-74 PET/CT)

  6. OGA & PDAC: impact on TNM stage

    Impact on TNM stage of \[18F\]AlF-FAPI-74 PET/CT compared to full staging (\[18F\]FDG PET/CT and conventional imaging) and impact of \[18F\]AlF-FAPI-74 PET/CT compared to only conventional imaging-based staging.

    Time frame: From enrollment to the end of the follow-up period (i.e. 12 months after first [18F]AlF-FAPI-74 PET/CT)

  7. OGA & PDAC: impact on clinical management

    Impact on clinical management.

    Time frame: From enrollment to the end of the follow-up period (i.e. 12 months after first [18F]AlF-FAPI-74 PET/CT)

  8. OGA & PDAC: impact on potential radiation therapy plan

    Impact on potential radiation therapy plan.

    Time frame: From enrollment to the end of the follow-up period (i.e. 12 months after first [18F]AlF-FAPI-74 PET/CT)

  9. OGA & PDAC: psychological impact

    Psychological impact on patient of \[18F\]AlF-FAPI-74 PET/CT procedure.

    Time frame: From enrollment to the end of the follow-up period (i.e. 12 months after first [18F]AlF-FAPI-74 PET/CT)

  10. OGA & PDAC: reproducibility

    Intra- and interobserver reproducibility of both \[18F\]FDG and \[18F\]AlF-FAPI-74 PET/CT.

    Time frame: From enrollment to the end of the follow-up period (i.e. 12 months after first [18F]AlF-FAPI-74 PET/CT)

  11. OGA & PDAC: adverse events

    Patient safety: adverse events of \[18F\]AlF-FAPI-74 PET/CT.

    Time frame: From enrollment to the end of the follow-up period (i.e. 12 months after first [18F]AlF-FAPI-74 PET/CT)

  12. OGA & PDAC: evolution between baseline and end of neo-adjuvant treatment

    Evolution between baseline and end of neo-adjuvant treatment in patients with 2 \[18F\]AlF-FAPI-74 scans: (i) number of lesion; (ii) uptake; (iii) TBR; (iv) TNM score;(v) treatment plan based on scan.

    Time frame: From enrollment to the end of the follow-up period (i.e. 12 months after first [18F]AlF-FAPI-74 PET/CT)

  13. OGA & PDAC: correlation with immunohistochemistry

    Correlation of \[18F\]AlF-FAPI-74 biodistribution with FAP tissue expression as measured by immunohistochemistry (IHC).

    Time frame: From enrollment to the end of the follow-up period (i.e. 12 months after first [18F]AlF-FAPI-74 PET/CT)

  14. Subgroup analysis OGA: lymph node detection

    Subgroup 1: Upfront resectable patients. Subgroup 2: Patients scheduled for neo-adjuvant therapy (mostly classified as locally advanced). Sensitivity, specificity, postivie predictive value, negative predictive value for lymph nodes.

    Time frame: From enrollment to the end of the follow-up period (i.e. 12 months after first [18F]AlF-FAPI-74 PET/CT)

  15. Subgroup analysis OGA: impact on TNM stage

    Subgroup 1: Upfront resectable patients. Subgroup 2: Patients scheduled for neo-adjuvant therapy (mostly classified as locally advanced). Impact on TNM stage of \[18F\]AlF-FAPI-74 PET/CT compared to \[18F\]FDG PET/CT-based stage.

    Time frame: From enrollment to the end of the follow-up period (i.e. 12 months after first [18F]AlF-FAPI-74 PET/CT)

  16. Subgroup analysis OGA: evolution between baseline and end of neo-adjuvant treatment

    Subgroup 2: Patients scheduled for neo-adjuvant therapy (mostly classified as locally advanced). Evolution between baseline and end of neo-adjuvant treatment in patients with 2 \[18F\]AlF-FAPI-74 scans: (i) number of lesion; (ii) uptake; (iii) TBR; (iv) TNM score; (v) treatment plan based on scan

    Time frame: From enrollment to the end of the follow-up period (i.e. 12 months after first [18F]AlF-FAPI-74 PET/CT)

  17. Subgroup analysis OGA: correlation with pathology

    Subgroup 2: Patients scheduled for neo-adjuvant therapy (mostly classified as locally advanced). Correlation of imaging parameters and their change with pathological assessment of resection specimen (pTNM stage, regression grade).

    Time frame: From enrollment to the end of the follow-up period (i.e. 12 months after first [18F]AlF-FAPI-74 PET/CT)

  18. Subgroup analysis PDAC: tumor detection

    Subgroup 1: Patients scheduled for neo-adjuvant therapy (mostly classified as borderline resectable or locally advanced). Subgroup 2: Metastatic patients. Sensitivity, specificity, positive predictive value, negative predictive value and accuracy for lymph nodes and distant metastases.

    Time frame: From enrollment to the end of the follow-up period (i.e. 12 months after first [18F]AlF-FAPI-74 PET/CT)

  19. Subgroup analysis PDAC: impact on TNM stage

    Subgroup 1: Patients scheduled for neo-adjuvant therapy (mostly classified as borderline resectable or locally advanced). Subgroup 2: Metastatic patients. Impact on TNM stage of \[18F\]AlF-FAPI-74 PET/CT compared to \[18F\]FDG PET/CT, CT or MRI-based stage.

    Time frame: From enrollment to the end of the follow-up period (i.e. 12 months after first [18F]AlF-FAPI-74 PET/CT)

  20. Subgroup analysis PDAC: evolution between baseline and end of neo-adjuvant treatment

    Subgroup 1: Patients scheduled for neo-adjuvant therapy (mostly classified as borderline resectable or locally advanced). Evolution between baseline and end of neo-adjuvant treatment in patients with 2 \[18F\]AlF-FAPI-74 scans: (i) number of lesion; (ii) uptake; (iii) TBR; (iv) TNM score; (v) treatment plan based on scan

    Time frame: From enrollment to the end of the follow-up period (i.e. 12 months after first [18F]AlF-FAPI-74 PET/CT)

  21. Subgroup analysis PDAC: correlation with pathology

    Subgroup 1: Patients scheduled for neo-adjuvant therapy (mostly classified as borderline resectable or locally advanced). Correlation of imaging parameters and their change with pathological assessment of resection specimen (pTNM stage, regression grade).

    Time frame: From enrollment to the end of the follow-up period (i.e. 12 months after first [18F]AlF-FAPI-74 PET/CT)

  22. Subgroup analysis PDAC: association with survival

    Subgroup 2: Metastatic patients. Association between total tumor burden on \[18F\]AlF-FAPI-74 PET/CT and survival. Association between semi-quantitative uptake measurements (maximal standardized uptake value (SUVmax), average SUV (SUVmean), peak SUV (SUVpeak) of tumoral lesions on \[18F\]AlF-FAPI-74 PET/CT and survival.

    Time frame: From enrollment to the end of the follow-up period (i.e. 12 months after first [18F]AlF-FAPI-74 PET/CT)

  23. Clinically Challenging Situation: detection rate

    Primary tumor/local recurrence, lymph node and distant metastases detection rate (compared to best value comparator) vs. \[18F\]FDG PET/CT.

    Time frame: From enrollment to the end of the follow-up period (i.e. 12 months after first [18F]AlF-FAPI-74 PET/CT)

  24. Clinically Challenging Situation: semi-quantitative uptake measurements

    Semi-quantitative uptake measurements (maximal standardized uptake value (SUVmax), average SUV. (SUVmean), peak SUV (SUVpeak)) of tumoral lesions on \[18F\]AlF-FAPI-74 PET/CT and \[18F\]FDG PET/CT

    Time frame: From enrollment to the end of the follow-up period (i.e. 12 months after first [18F]AlF-FAPI-74 PET/CT)

  25. Clinically Challenging Situation: tumor-to-background uptake values

    Tumor-to-background uptake values (SUV lesion divided by SUV background) on \[18F\]AlF-FAPI-74 PET/CT and \[18F\]FDG PET/CT, using following background organs: liver, lung, gluteus muscle, mediastinal bloodpool, bowel, bone marrow (L4 if no abnormal uptake).

    Time frame: From enrollment to the end of the follow-up period (i.e. 12 months after first [18F]AlF-FAPI-74 PET/CT)

  26. Clinically Challenging Situation: impact on potential radiation therapy plan

    Impact on potential radiation therapy plan of \[18F\]AlF-FAPI-74 PET/CT vs. \[18F\]FDG PET/CT.

    Time frame: From enrollment to the end of the follow-up period (i.e. 12 months after first [18F]AlF-FAPI-74 PET/CT)

  27. Clinically Challenging Situation: reproducibility

    Intra- and interobserver reproducibility.

    Time frame: From enrollment to the end of the follow-up period (i.e. 12 months after first [18F]AlF-FAPI-74 PET/CT)

  28. Clinically Challenging Situation: adverse events

    Patient safety: adverse events.

    Time frame: From enrollment to the end of the follow-up period (i.e. 12 months after first [18F]AlF-FAPI-74 PET/CT)

07

Study locations

2 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2025 (actual). Primary completion is estimated for Dec 2027, 34 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2025
First posted
Jan 17, 2025
StartActual
Feb 6, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • University Hospital Ghent · Ghent, Belgium
Show 1 removed
  • University Hospital Ghent · Gent, Belgium
Nov 6, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • University Hospital Antwerp (UZA) · Edegem, BelgiumContact added (no phone or email listed)
  • UZ Leuven · Leuven, BelgiumContact person changed (no phone or email listed)
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    1 site added, 1 site removed
    Show site
    • University Hospital Ghent · Ghent, Belgium
    Show 1 removed
    • University Hospital Ghent · Gent, Belgium
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • University Hospital Antwerp (UZA) · Edegem, BelgiumContact added (no phone or email listed)
    • UZ Leuven · Leuven, BelgiumContact person changed (no phone or email listed)
    + 3 other changes: verification date, oversight details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06782412
Lead sponsor
KU Leuven
Responsible party
Christophe Deroose, Prof. Dr. (Head of Clinic Nuclear Medicine, UZ Leuven - Full Professor, KU Leuven, KU Leuven) — Principal investigator
First posted
Jan 17, 2025
Start date
Feb 6, 2025
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion